Kowa's New Drug Application (NDA) for drug K-911 was accepted by the FDA for review.
2 reports, 1 independent
Updated Aug 28
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Kowa's New Drug Application (NDA) for drug K-911 was accepted by the FDA for review.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
Related events
- The FDA is reviewing a drug approval application for a condition involving the company GAD.
- The FDA recommended advancement for a new drug application submitted by a company.
- The FDA and European Medicines Agency are harmonizing regulatory review of drug applications.
- Data was presented in Athens supporting a future U.S. NDA submission to the FDA.
- The FDA is reviewing drug data and company resubmissions, while also overseeing the functions of the U.S. Department of Health and Human Services.